You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Episode 3: Addressing Common Challenges in Anticoagulation in Atrial Fibrillation

  • Authors: Tatjana Potpara, MD, PhD; Susan J. Mayor, PhD
  • CME / ABIM MOC Released: 8/27/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/27/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, and neurologists.

The goal of this activity is to provide the latest information on how to manage non-vitamin K antagonist oral anticoagulant (NOAC) dosage in patients with atrial fibrillation (AF) undergoing a procedure, especially percutaneous coronary intervention.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Common challenges associated with treatment strategies for stroke prevention in patients with AF


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Tatjana Potpara, MD, PhD

    Assistant Professor of Internal Medicine and Cardiology
    Belgrade University
    Head of Department for Intensive Care in Cardiac Arrhythmias
    Cardiology Clinic
    Clinical Centre of Serbia
    Belgrade, Serbia

    Disclosures

    Disclosure: Tatjana Potpara, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer; Pfizer

  • Susan J. Mayor, PhD

    Medical Journalist
    London, United Kingdom

    Disclosures

    Disclosure: Susan J. Mayor, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eisai Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Mundipharma; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Sanofi-Aventis Pasteur MSD
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bayer HealthCare Pharmaceuticals; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; Novo Nordisk

Anticoagulation Management Steering Committee

  • Keith A.A. Fox, MBChB, FRCP, FMedSci

    Professor of Cardiology
    University of Edinburgh
    Edinburgh, United Kingdom

    Disclosures

    Disclosure: Keith A.A. Fox, MBChB, FRCP, FMedSci, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare; Janssen Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi; Verseon Corporation
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Janssen Pharmaceuticals
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Janssen Pharmaceuticals

  • A. John Camm, MD

    Professor
    St. George's University of London
    London, United Kingdom

    Disclosures

    Disclosure: A. John Camm, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company/Pfizer Inc.; Daiichi Sankyo, Inc.
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Daiichi Sankyo, Inc.
    Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company/Pfizer Inc.; Daiichi Sankyo, Inc.

  • Craig I. Coleman, PharmD

    Professor
    University of Connecticut
    Storrs, Connecticut, United States

    Disclosures

    Disclosure: Craig I. Coleman, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer AG; Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Bayer AG; Janssen Pharmaceuticals, Inc.
    Received grants for clinical research from: Bayer AG; Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.

  • Dominique Farge-Bancel, MD

    Professor of Internal Medicine and Vascular Disease
    Hôpital Saint-Louis, AP-HP
    Paris University France
    McGill University
    Montreal, Quebec, Canada

    Disclosures

    Disclosure: Dominique Farge-Bancel, MD, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Bayer; Leo Pharma
    Received grants for clinical research from: Aspen Pharmacare; Leo Pharma; Pfizer

  • Alok A. Khorana, MD

    Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Case Western Reserve University
    Sondra and Stephen Hardis Chair in Oncology Research
    Vice Chair (Clinical Services)
    Director
    GI Malignancies Program
    Taussig Cancer Institute
    Cleveland Clinic
    Cleveland, Ohio, United States

    Disclosures

    Disclosure: Alok A. Khorana, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AngioDynamics; Bayer HealthCare; Halozyme Therapeutics; Janssen Pharmaceuticals; Medtronic, Inc.; Pharmacyclics; PharmaCyte; Seattle Genetics, Inc.
    Received grants for clinical research from: Amgen Inc.; Array; Bristol-Myers Squibb Company; Leap

  • Christian T. Ruff, MD, MPH

    Assistant Professor of Medicine
    Harvard Medical School
    Director of General Cardiology
    Cardiovascular Division
    TIMI Study Group
    Brigham and Women's Hospital
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Christian T. Ruff, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Anthos; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; MedImmune Inc.; Pfizer Inc.; Portola Pharmaceuticals
    Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; MedImmune Inc.

  • Peter Verhamme, MD, PhD

    Professor
    University of Leuven
    Leuven, Belgium

    Disclosures

    Disclosure: Peter Verhamme, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.; Portola Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.
    Received grants for clinical research from: Bayer; Bristol-Myers Squibb Company; Pfizer Inc.

Vascular Protection Steering Committee

  • Keith A.A. Fox, MBChB, FRCP, FMedSci

    As listed above

  • Victor Aboyans, MD, PhD

    Professor
    Head of Department of Cardiology
    Dupuytren University Hospital
    Limoges, France

    Disclosures

    Disclosure: Victor Aboyans, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer AG; Novo Nordisk; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company/Pfizer Inc.; Novartis Pharmaceuticals Corporation

  • Deepak L. Bhatt, MD, MPH

    Professor of Medicine
    Harvard Medical School
    Executive Director of Interventional Cardiovascular Programs
    Brigham and Women's Hospital Heart & Vascular Center
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Abbott Laboratories; Afimmune; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cardax; Chiesi Pharmaceuticals, Inc.; CSL Behring; Eisai Inc.; Ethicon, Inc.; Ferring Pharmaceuticals; Forest Laboratories, Inc.; Fractyl; Idorsia; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Pfizer Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Synatic; The Medicines Company

  • John W.A. Eikelboom, MBBS, MSc

    Professor
    McMaster University
    Hamilton, Ontario, Canada

    Disclosures

    Disclosure: John W.A. Eikelboom, MBBS, MSc, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi; SERVIER
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi

  • Manesh R. Patel, MD

    Professor of Medicine
    Duke University Medical Center
    Durham, North Carolina, United States

    Disclosures

    Disclosure: Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Janssen Pharmaceuticals; Mytonomy; Procyrion, Inc.
    Received grants for clinical research from: Bayer HealthCare; Janssen Pharmaceuticals; Medtronic, Inc.

  • Robert C. Welsh, MD, FRCPC

    Professor of Medicine
    University of Alberta in Edmonton
    Director of Cardiac Catheterization and Interventional Cardiology
    Mazankowski Alberta Heart Institute
    Edmonton, Alberta, Canada

    Disclosures

    Disclosure: Robert C. Welsh, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company/Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Sanofi
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare

Editors

  • Caroline M. Padbury, BPharm

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Caroline M. Padbury, BPharm, has disclosed no relevant financial relationships.

  • Ian List

    Medical Writer, Cambridge, Massachusetts

    Disclosures

    Disclosure: Ian List has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories


Accreditation Statements

Medscape
 
Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Episode 3: Addressing Common Challenges in Anticoagulation in Atrial Fibrillation

Authors: Tatjana Potpara, MD, PhD; Susan J. Mayor, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 8/27/2020

Valid for credit through: 8/27/2021, 11:59 PM EST

processing....

Abbreviations

ACS = acute coronary syndrome
AF = atrial fibrillation
CAD = coronary artery disease
CrCl = creatinine clearance
EHRA = European Heart and Rhythm Association
EP = electrophysiology
ICD = implantable cardioverter defibrillator
ICH = intracerebral hemorrhage
MI = myocardial infarction
NOAC = non-vitamin K antagonist oral anticoagulant
OAC = oral anticoagulant
PCI = percutaneous coronary intervention
RCT = randomized controlled trial
VKA = vitamin K antagonist

« Return to: Episode 3: Addressing Common Challenges in Anticoagulation in Atrial Fibrillation
  • Print